Abstracts Archive - Page 1450 of 2607 - ACR Meeting Abstracts

Abstract Number: 941 • 2017 ACR/ARHP Annual Meeting
Ro/SSA Autoantibody Exposed Neonates Have an Expansion of NK Cells and a Discernible Type II IFN Signature with High IFNγ in Peripheral Blood
Margarita Ivanchenko¹, Malin Hedlund¹, Gudny Ella Thorlacius¹, Vijole Ottosson¹, Karine Chemin², Sven-Erik Sonesson³ and Marie Wahren-Herlenius¹, ¹Unit of Experimental Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³Pediatric Cardiology Unit, Department of Women´s and Children´s Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Congenital heart block (CHB) may develop in the fetus of women with Ro/SSA autoantibodies. The mothers are commonly diagnosed with Sjögren’s syndrome or SLE.…
Abstract Number: 942 • 2017 ACR/ARHP Annual Meeting
Role of the Pyrin Inflammasome in Resistance to Yersinia Pestis: A Possible Selective Advantage for Carriers of MEFV Mutations
Yong Hwan Park¹, Wonyong Lee¹, Lawton Chung², James Bliska², Daniel L. Kastner¹ and Jae Jin Chae³, ¹Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²Department of Molecular Genetics and Microbiology, School of Medicine, Stony Brook University, Stony Brook, NY, ³Inflammatory disease section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Mutations in MEFV, encoding pyrin, cause the prototypic autoinflammatory disease, familial Mediterranean fever (FMF). The carrier frequency of FMF-associated MEFV mutations is extraordinarily high…
Abstract Number: 943 • 2017 ACR/ARHP Annual Meeting
The Course of the Forced Vital Capacity during Treatment for Systemic Sclerosis-Related Interstitial Lung Disease Predicts Long-Term Survival in 2 Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Dinesh Khanna², Michael Roth³, Philip J. Clements³, Daniel E. Furst¹, Lynette Keyes-Elstein⁴, Ashley Pinckney⁴, Ellen Goldmuntz⁵, Robert Elashoff⁶ and Keith Sullivan⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Rho Federal Systems, Inc., Chapel Hill, NC, ⁵NIAID, NIH, Bethesda, MD, ⁶University of California, Los Angeles, Los Angeles, CA, ⁷Duke University, Durham, NC
Background/Purpose: While prior observational studies have identified predictors of mortality in systemic sclerosis-interstitial lung disease (SSc-ILD), no studies have evaluated predictors of long-term mortality in…
Abstract Number: 944 • 2017 ACR/ARHP Annual Meeting
Long-Term Survival and Follow-up of Anti-Th/to Antibody Positive Systemic Sclerosis Patients
Devon Charlton¹, Maureen Laffoon², Thomas A. Medsger Jr.³ and Robyn T. Domsic⁴, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Anti-Th/To antibody is an autoantibody associated with systemic sclerosis (SSc), occurring in 5-10% of patients. To date, only relatively small case series have described…
Abstract Number: 945 • 2017 ACR/ARHP Annual Meeting
Autoantibodies to the hPOP1 and Rpp25/38 Components of the Th/to Complex Identify a Subgroup of Systemic Sclerosis (SSc) Associated Interstitial Lung Disease (ILD) and Antibodies to hPOP1 Are Associated with Reduced Survival
Jennifer G Walker¹, Mandana Nikpour², Molla Huq³, Karen Patterson¹, Peter Roberts-Thomson⁴, Susanna Proudman⁵, Wendy Stevens⁶, Susan Lester⁷, Maureen Rischmueller⁸, Jane Zochling⁹, Joanne Sahhar¹⁰, Peter Nash¹¹, Janet Roddy¹², Catherine Hill¹³, Marie Hudson¹⁴, Murray Baron¹⁵, Janet E. Pope¹⁶, Maureen D. Mayes¹⁷, Shervin Assassi¹⁸, Michael Mahler¹⁹ and Marvin J. Fritzler²⁰, ¹Flinders University of South Australia, Adelaide, Australia, ²Melbourne University, Melbourne, Australia, ³Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, ⁴Immunology, Flinders University of South Australia, Adelaide, Australia, ⁵University of Adelaide, Adelaide, Australia, ⁶Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁷Queen Elizabeth Hospital, Adelaide, Australia, ⁸Medicine, University of Adelaide, Adelaide, Australia, ⁹Menzies Institute for Medical Research, Tasmania, Hobart, Australia, ¹⁰Department of Rheumatology, Monash Medical Centre, Melbourne, Australia, ¹¹University of Queensland, Brisbane, Australia, ¹²Royal Perth Hospital, Perth, Australia, ¹³Medicine, The University of Adelaide, Adelaide, Australia, ¹⁴Division of Rheumatology, Jewish General Hospital, Lady David Institute for Medical Research, Montreal, QC, Canada, ¹⁵Medicine, McGill University, Quebec, Montreal, QC, Canada, ¹⁶Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ¹⁷Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ¹⁸University of Texas McGovern Medical School, Houston, TX, ¹⁹Research and Development, Inova Diagnostics, San Diego, CA, ²⁰Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: The clinical associations of anti-Th/To antibodies (Abs) are not fully established, and until recently immunoprecipitation (IP) was the only reliable assay. Using IP, anti-Th/To…
Abstract Number: 946 • 2017 ACR/ARHP Annual Meeting
Clinical and Serological Features of Systemic Sclerosis in a Multicenter African American Cohort: Analysis of the Genome Research in African American Scleroderma Patients Clinical Database
Nadia D. Morgan¹, Ami A. Shah¹, Maureen D. Mayes², Robyn T. Domsic³, Thomas A. Medsger Jr.⁴, Virginia D. Steen⁵, John Varga⁶, Mary A. Carns⁷, Paula S. Ramos⁸, Richard M. Silver⁹, Elena Schiopu¹⁰, Dinesh Khanna¹⁰, Vivien Hsu¹¹, Jessica K. Gordon¹², Heather Gladue¹³, Lesley A. Saketkoo¹⁴, Lindsey A. Criswell¹⁵, Chris T. Derk¹⁶, Marcin A. Trojanowski¹⁷, Victoria K. Shanmugam¹⁸, Lorinda Chung¹⁹, Antonia Valenzuela²⁰, Reem Jan²¹, Avram Goldberg²², Elaine F. Remmers²³, Daniel L. Kastner²³, Fredrick M. Wigley²⁴, Pravitt Gourh²⁵ and Francesco Boin²⁶, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ³Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁶Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁷Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁸Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ⁹Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ¹²Rheumatology, Hospital for Special Surgery, New York, NY, ¹³Rheumatology, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ¹⁴Rheumatology, Tulane University School of Medicine, New Orleans, LA, ¹⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ¹⁶Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁷Boston University School of Medicine, Boston, MA, ¹⁸Rheumatology, The George Washington University, Washington, DC, ¹⁹Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²⁰Stanford University School of Medicine, Stanford, CA, ²¹Medicine, Rheumatology, University of Chicago, Chicago, IL, ²²NYU Langone Medical Center, New York, NY, ²³National Institutes of Health (NIH), National Human Genome Research Institute, Bethesda, MD, ²⁴Rheum Div/Mason F Lord, Johns Hopkins University, Baltimore, MD, ²⁵NIAMS-Rheumatology, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²⁶Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Racial differences exist in the severity of systemic sclerosis (SSc). To enhance our knowledge about SSc in African Americans, we established a comprehensive clinical…
Abstract Number: 947 • 2017 ACR/ARHP Annual Meeting
Norway As a National Reference Population for Systemic Sclerosis; Preliminary Results from a Complete, Nationwide Cohort
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim¹, Anne Kristine Halse², Marit Seip³, Marianne Wallenius⁴, Helle Bitter⁵, Torhild Garen¹, Oyvind Midtvedt¹ and Øyvind Molberg¹, ¹Oslo University Hospital, Oslo, Norway, ²Haukeland University Hospital, Bergen, Norway, ³University Hospital of North Norway, Tromso, Norway, ⁴St. Olav's University Hospital, Trondheim, Norway, ⁵Hospital of Southern Norway, Kristiansand, Norway
Background/Purpose: To fully understand the impact of Systemic sclerosis (SSc) there is a need to complement existing multi-center registry data with novel, unbiased, high resolution…
Abstract Number: 948 • 2017 ACR/ARHP Annual Meeting
Application of a Diagnostic Algorithm to Identify Inflammatory Myopathy in Systemic Sclerosis
Vandana Bhushan^1,2, Adam Maundrell¹, Charlotte Proudman^1,2, Leah McWilliams¹, Llew Spargo¹, Robert Metcalf¹, Jennifer Walker³, Mandana Nikpour^4,5, Wendy Stevens⁴, Vidya Limaye^1,2 and Susanna Proudman^1,2, ¹Rheumatology Unit, Royal Adelaide Hospital, South Australia, Adelaide, Australia, ²Discipline of Medicine, University of Adelaide, South Australia, Adelaide, Australia, ³Flinders University of South Australia, Adelaide, Australia, ⁴St Vincent's Hospital, Melbourne, Victoria, Melbourne, Australia, ⁵Department of Medicine, University of Melbourne, Victoria, Melbourne, Australia
Background/Purpose: Muscle involvement in systemic sclerosis (SSc) is under-recognised and poorly understood. Reported prevalence varies up to 15%, reflecting lack of consistent definition, the heterogeneous…
Abstract Number: 949 • 2017 ACR/ARHP Annual Meeting
Sequence Homology and Immune Reactivity between T Cell Epitopes of Related Gut Microbes and Two Novel Autoantigens Provide a Link between Microbial and Host Immunity in Patients with Rheumatoid Arthritis
Annalisa Pianta¹, Sheila Arvikar², Klemen Strle³, Elise E. Drouin¹, Qi Wang⁴, Catherine E. Costello⁴ and Allen C. Steere⁵, ¹Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, BOSTON, MA, ³Department of Immunology and Inflammatory Diseases, Massachusetts General Hospital, BOSTON, MA, ⁴Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, MA, ⁵Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: It has been proposed that immunological triggers at mucosal sites, such as the gut microbiota, may promote autoimmunity affecting joints in patients with rheumatoid…
Abstract Number: 950 • 2017 ACR/ARHP Annual Meeting
Identification of Naturally Processed Immunodominant Topoisomerase I Epitopes in Patients with Systemic Sclerosis
Eleni Tiniakou¹, Andrea Fava², Tara Guhr³, Francesco Boin⁴ and Erika Darrah⁵, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³University of North Carolina, Chapel Hill, NC, ⁴Rheumatology, University California, San Francisco, San Francisco, CA, ⁵Department of Medicine/Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Identification of immunodominant T cell epitopes of autoantigens is crucial to understanding the pathogenesis of autoimmune diseases and developing disease-specific diagnostic and therapeutic tools.…
Abstract Number: 951 • 2017 ACR/ARHP Annual Meeting
Cross Sectional Analysis of Citrullinated-Synovial Antigen-Specific CD4+ T Cells in an RA Cohort Demonstrates Antigen Based Differences in T Cell Frequency, Phenotype and the Influence of Immunotherapy
Cliff Rims¹, Sylvia Posso¹, Bernard Ng², Jeffrey Carlin³, Eddie James⁴ and Jane H. Buckner⁴, ¹Translational Research, Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Rheumatology, VA Puget Sound Healthcare System, Seattle, WA, ³Rheumatology, Virginia Mason Medical Center, Seattle, WA, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: The presence of ACPA in RA indicates that an immune response directed toward citrullinated synovial antigens participates in disease development or persistence. Research from…
Abstract Number: 952 • 2017 ACR/ARHP Annual Meeting
Serine Arginine-Rich Splicing Factor 1 (SRSF1) Is a Novel Regulator of T Lymphocyte Homeostasis In Vivo and Its Deficiency Associates with Lymphopenia in SLE Patients
Takayuki Katsuyama¹, Michael W. Mosho¹, Andrew R. Gillooly², George C. Tsokos¹ and Vaishali R. Moulton³, ¹Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Medicine/ Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Lymphopenia is a common clinical feature in patients with systemic lupus erythematosus (SLE), and associates with high disease activity and comorbidities including infections. However,…
Abstract Number: 953 • 2017 ACR/ARHP Annual Meeting
Persistence of Pathogenic CD4 Memory T Cells Revealed through Cytometry Time of Flight in Juvenile Idiopathic Arthritic Patients with Disease Resurgence upon Withdrawal of Anti-TNFA Biologics
Jing Yao Leong¹, Joo Guan Yeo², Phyllis Chen³, Liyun Lai⁴, Fauziah Ally⁵, Loshinidevi D/O Thana Bathi³, Justin Hung Tiong Tan², Thaschawee Arkachaisri², Femke van Wijk⁶, Salvatore Albani⁴, Daniel J Lovell⁷ and Gerdien Mijnheer⁸, ¹SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ²Rheumatology and Immunology Service, KK Women's and Children's Hospital, Singapore, Singapore, ³Singhealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ⁴SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ⁵STIIC, SingHealth Translational Immunology and Inflammation Centre, Singapore, Singapore, ⁶University Medical Center Utrecht, Utrecht, Netherlands, ⁷Rheumatology, PRCSG - Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, ⁸1Laboratory of Translational Immunology, Department of Paediatric Immunology, , The Netherlands, University Medical Centre Utrecht, Wilhelmina Children’s Hospital, Utrecht, Netherlands
Background/Purpose: Treatment of polyarticular JIA with anti-TNFA biologics has experienced significant success, with up to 80% of patients demonstrating clinically meaningful efficacy. Yet concerns regarding…
Abstract Number: 954 • 2017 ACR/ARHP Annual Meeting
Microrna-21 Is a Critical Regulator of Autoimmunity through Promoting Effector and Metabolic Function of Pathogenic TH17 Cells
Xiang Yu¹ and Nan Shen^1,2,3, ¹Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, and Shanghai Jiao Tong University, Shanghai, China, ²Institute of Health Sciences, Shanghai Jiao Tong University School of Medicine and Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China, ³Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease that causes mortality and morbidity worldwide. Recent studies suggest proinflammatory TH17 cells are key pathogenic…
Abstract Number: 955 • 2017 ACR/ARHP Annual Meeting
In Vitro Effects of CR6086, a Potent ProstaglandinE2 Subtype 4 Receptor Antagonist, on Bone Erosive Pathways
Tiziana Piepoli¹, Mario Montagna¹, Daniele Maggioni¹, Silvia Zerbi¹, Laura Mennuni¹, Marco Lanza¹, Gianfranco Caselli¹ and Lucio C. Rovati², ¹Rottapharm Biotech, Monza, Italy, ²Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: CR6086 is a selective EP4 receptor antagonist immunomodulator in clinical development for rheumatoid arthritis (RA). In animal models of RA, it demonstrated a superior…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].